Insider Buying: Burning Rock Biotech (NASDAQ:BNR) Director Acquires 210,000 Shares

Burning Rock Biotech Limited Sponsored ADR (NASDAQ:BNR) Director Yusheng Han acquired 210,000 shares of the stock in a transaction that occurred on Friday, June 12th. The stock was acquired at an average cost of $9.25 per share, for a total transaction of $1,942,500.00. Following the completion of the purchase, the director owned 17,907,436 shares in the company, valued at $165,643,783. The trade was a 1.19% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Yusheng Han also recently made the following trade(s):

• On Friday, June 26th, Yusheng Han bought 24,900 shares of Burning Rock Biotech stock. The stock was bought at an average cost of $8.00 per share, for a total transaction of $199,200.00.
• On Wednesday, June 24th, Yusheng Han acquired 250,000 shares of Burning Rock Biotech stock. The shares were bought at an average cost of $8.00 per share, for a total transaction of $2,000,000.00.
• On Tuesday, June 23rd, Yusheng Han purchased 5,990 shares of Burning Rock Biotech stock. The shares were purchased at an average cost of $7.50 per share, for a total transaction of $44,925.00.
• On Monday, June 22nd, Yusheng Han bought 104,650 shares of Burning Rock Biotech stock. The shares were purchased at an average price of $7.45 per share, for a total transaction of $779,642.50.
• On Tuesday, June 16th, Yusheng Han acquired 111,110 shares of Burning Rock Biotech stock. The shares were acquired at an average price of $9.00 per share, for a total transaction of $999,990.00.
• On Thursday, June 11th, Yusheng Han purchased 24,760 shares of Burning Rock Biotech stock. The stock was acquired at an average price of $8.74 per share, with a total value of $216,402.40.

Burning Rock Biotech Price Performance

Burning Rock Biotech stock opened at $8.96 on Thursday. Burning Rock Biotech Limited Sponsored ADR has a 1 year low of $3.22 and a 1 year high of $41.72. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.81 and a current ratio of 3.05. The firm has a 50 day moving average price of $12.79 and a 200 day moving average price of $20.08. The company has a market cap of $94.26 million, a price-to-earnings ratio of -10.93 and a beta of 1.33.

Burning Rock Biotech (NASDAQ:BNR) last announced its quarterly earnings results on Tuesday, June 9th. The company reported ($0.20) EPS for the quarter, topping the consensus estimate of ($2.29) by $2.09. The company had revenue of $15.66 million during the quarter, compared to analyst estimates of $19.21 million. Burning Rock Biotech had a negative return on equity of 10.98% and a negative net margin of 11.57%.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of BNR. Marshall Wace LLP bought a new position in Burning Rock Biotech during the fourth quarter valued at about $220,000. Renaissance Technologies LLC raised its position in Burning Rock Biotech by 13.8% in the first quarter. Renaissance Technologies LLC now owns 35,407 shares of the company’s stock worth $571,000 after acquiring an additional 4,290 shares in the last quarter. Prospera Financial Services Inc lifted its holdings in Burning Rock Biotech by 26.0% in the 4th quarter. Prospera Financial Services Inc now owns 31,185 shares of the company’s stock valued at $628,000 after acquiring an additional 6,430 shares during the last quarter. Finally, Crcm LP lifted its holdings in Burning Rock Biotech by 13.8% in the 3rd quarter. Crcm LP now owns 221,575 shares of the company’s stock valued at $1,917,000 after acquiring an additional 26,809 shares during the last quarter. 30.03% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms recently commented on BNR. Wall Street Zen downgraded Burning Rock Biotech from a “buy” rating to a “hold” rating in a research note on Saturday, June 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of Burning Rock Biotech in a report on Monday, April 20th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company has an average rating of “Sell”.

About Burning Rock Biotech

Burning Rock Biotech (NASDAQ: BNR) is a precision oncology company specializing in the development and commercialization of next-generation sequencing (NGS)–based cancer diagnostics. The company’s core business revolves around liquid biopsy tests, which analyze circulating tumor DNA (ctDNA) from blood samples to detect genetic mutations associated with various solid tumors. By enabling noninvasive profiling of tumor genomics, Burning Rock Biotech aims to guide personalized therapy decisions and monitor treatment response in cancer patients.

Founded in 2014 and headquartered in Guangzhou, China, Burning Rock Biotech launched its first clinical services in the mid-2010s and subsequently expanded its laboratory network across major Chinese cities.